NCT00407433已完成2 期
Phase 2 Single-Arm Studies of Gemcitabine in Combination With Oxaliplatin Refractory and Relapsed Pediatric Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 156
- 试验地点
- 1
- 主要终点
- The primary endpoint for efficacy is the percentage of patients achieving complete or partial response according to WHO guidelines, after having received 4 cycles of gemcitabine-oxaliplatin (8 weeks).
研究概览
简要总结
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 20 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed malignant solid tumor (at diagnosis)
- •Relapsed or refractory tumors in which correct standard treatment approaches have failed
- •Measurable primary and/or metastatic disease: at least one bi-dimensionally measurable lesion. For patients with neuroblastoma, measurable disease will be defined by the modified International Neuroblastoma Staging System (Brodeur et al.1993). For patients with osteosarcoma, measurable lesions are lung metastases and osseous lesions with soft tissue tumor, in exclusion of completely calcified or necrosed lesion at study entry. A patient with an unique osseous lesion without soft tissue mass can be included in the study if the lesion is operable and thus accessible for histological response assessment.
- •No more than one salvage therapy for relapse
- •Age at inclusion: 6 months to ≤ 20 years
- •Lansky play score ≥ 70% or ECOG performance status ≤ 1
- •Life expectancy ≥ 3 months
- •Adequate organ function:
- •Adequate hematological function: neutrophil count >= 1.0 x 10^9/L, platelet count >= 100 x 10^9/L; in case of bone marrow disease: >= 75 x 10^9/L; hemoglobin >= 8 g/dL
- •Adequate renal function: creatinine > 1.5 x ULN for age; If serum creatinine is > 1.5 ULN of age, then creatinine clearance (or radioisotope GFR) must be > 70 ml/min/1.73 m2 Adequate hepatic function: bilirubin > 1.5 x ULN; AST and ALT > 2.5 x ULN (AST, ALT ≤ 5 x ULN in case of liver metastases).
- •Wash out of 3 weeks in case of prior chemotherapy, 6 weeks if treatment included nitrosoureas, 2 weeks in case of vincristine alone; 4 weeks in case of prior radiotherapy. Patients must have recovered from the acute toxic effects of all prior therapy before enrollment into the study.
- •Able to comply with scheduled follow-up and with management of toxicity
- •All patients with reproductive potential must practice an effective method of birth control while on study. Female patients with childbearing potential must have a negative pregnancy test within 7 days before study treatment.
- •Written informed consent from patient, parents or legal guardian
排除标准
- •Concurrent administration of any other antitumor therapy.
- •Have previously completed or withdrawn from this study or any other study investigating gemcitabine or oxaliplatin.
- •Have a serious concomitant systemic disorder (for example, active infection including HIV or cardiac disease) that in the opinion of the investigator, would compromise the patient's ability to complete the study
- •Pre-existing sensory or motor neuropathy >Grade 2 (excluding neuropathy due to disease and/or surgery)
- •History of allergic reaction to platinum compounds
- •Are pregnant or breast feeding
- •Presence of symptomatic brain metastases in patients with solid non-central nervous system (CNS) tumors
结局指标
主要结局
The primary endpoint for efficacy is the percentage of patients achieving complete or partial response according to WHO guidelines, after having received 4 cycles of gemcitabine-oxaliplatin (8 weeks).
次要结局
- The secondary efficacy variables are the duration of response, the time to treatment failure, the time to progressive disease and the overall survival.
- Clinical and laboratory toxicities/symptomatology will be graded according to NCI-Common toxicity criteria AE v3.0
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast CancerBreast CancerNCT00674206Emory University6
终止
2 期
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial TractCarcinoma, Transitional CellNCT00127595Gustave Roussy, Cancer Campus, Grand Paris28
进行中（未招募）
1 期
Fase II trial with gemcitabine and oxaliplatin in patients with unknown primary tumours - UPT - unfitTo test the effect of Gemcitabine and axaliplatin in patients with unknown primary tumours and performance 2 or age 66 to 75EUCTR2005-001959-38-DKGedske Daugaard39
已完成
2 期
Efficacy Study of GEMOX Combination and Vinorelbine in NSCL PatientsNon Small Cell Lung CancerNCT00271271Sanofi40
已完成
2 期
Phase II study of gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced biliary tract cancer (JASPAC02)gemcitabine refractory advanced biliary tract cancerJPRN-UMIN000003650Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)40